Ignite Creation Date:
2024-05-06 @ 6:58 PM
Last Modification Date:
2024-10-26 @ 2:57 PM
Study NCT ID:
NCT05841992
Status:
RECRUITING
Last Update Posted:
2023-05-03
First Post:
2023-04-12
Brief Title:
Al18F-PSMA-617 and 68Ga-PSMA-617 PETCT Imaging in the Same Group of Prostate Cancer Patients
Sponsor:
Peking Union Medical College Hospital
Organization:
Peking Union Medical College Hospital
Study Overview
Official Title:
Comparison of the Detection Efficiencies of Al18F-PSMA-617 and 68Ga-PSMA-617 PETCT in Patients With Prostate Cancer
Status:
RECRUITING
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
18F-labeled prostate-specific membrane antigen PSMA ligand-positron emission tomography PET offers advantages over 68Ga-labeled PSMA ligands Al18F-PSMA-617 is a novel 18F-PSMA compound used for prostate cancer PCa imaging This pilot study was prospectively designed to compare the lesion detectability of Al18F-PSMA-617 and related 68Ga-PSMA-617 PETCT in patients with PCa
Detailed Description:
Prostate cancer PC is one of the most common malignancies worldwide in men with persistently high numbers dying from this disease Due to low levels of glycolysis in prostate cancer cell the uses of 18F-FDG PETCT to detect prostate cancer and its metastases are limited Prostate specific membrane antigen PSMA as known as folate hydrolase I or glutamate carboxypeptidase II is overexpressed on the cells of prostatic adenocarcinoma Various low molecular weight radiopharmaceuticals targeting PSMA such as PSMA-617 PSMA-11 for 68Ga-labeling have been developed 68Ga-PSMA PETCT has demonstrated desirable sensitivity and specificity in the detection of prostate cancer lesions which can find many micro lesions that cannot be identified by CT MRI and bone scan Al18F-PSMA-617 is a novel radiopharmaceutical targeting PSMA Liu T etal had demonstrated that Al18F-PSMA-617 accumulates specifically in PSMA-positive tumors with high binding affinity and selectivity The first in-human evaluation of Al18F-PSMA-617 in a small PCa sample size also confirmed the good detectability of tumor lesions This pilot study was prospectively designed to evaluate the early dynamic distribution of Al18F-PSMA-617 compared with 68Ga-PSMA-617 in the same group of prostate cancer patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None